MCID: BRN022
MIFTS: 59

Bronchiectasis

Categories: Genetic diseases, Respiratory diseases

Aliases & Classifications for Bronchiectasis

MalaCards integrated aliases for Bronchiectasis:

Name: Bronchiectasis 12 73 29 54 6 44 15 62 70 32
Polynesian Bronchiectasis 12
Kartagener Syndrome 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9563
ICD9CM 34 494
MeSH 44 D001987
NCIt 50 C84475
SNOMED-CT 67 155580000
ICD10 32 J47
UMLS 70 C0006267 C0022521

Summaries for Bronchiectasis

PubMed Health : 62 About bronchiectasis: Bronchiectasis (brong-ke-EK-tah-sis) is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of your lungs. Bronchiectasis often is caused by an infection or other condition that injures the walls of the airways or prevents the airways from clearing mucus. Mucus is a slimy substance. It helps remove inhaled dust, bacteria, and other small particles from the airways. In bronchiectasis, your airways slowly lose their ability to clear out mucus. The mucus builds up, and bacteria begin to grow. This leads to repeated, serious lung infections. Each infection causes more damage to the airways. Over time, the airways can't properly move air in and out of the lungs. As a result, the body's vital organs might not get enough oxygen. Bronchiectasis can lead to serious health problems, such as respiratory failure, atelectasis (at-eh-LEK-tah-sis), and heart failure.

MalaCards based summary : Bronchiectasis, also known as polynesian bronchiectasis, is related to idiopathic bronchiectasis and bronchiectasis with or without elevated sweat chloride 1, and has symptoms including headache An important gene associated with Bronchiectasis is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways are Innate Immune System and Defensins. The drugs Fluticasone and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include lung, neutrophil and kidney, and related phenotypes are immune system and mortality/aging

Disease Ontology : 12 A bronchial disease that is a chronic inflammatory condition of one or more bronchi or bronchioles marked by dilatation and loss of elasticity of the walls resulting from damage to the airway wall leading to the formation of small sacs on the bronchial wall and impairment of cilia mobility in the lung. Inflammation of the bronchial wall increases mucus secretion which serves as a breeding ground for bacteria. Bronchiectasis is caused by repeated respiratory infections, immune deficiency disorders, hereditary disorders (cystic fibrosis or primary ciliary dyskinesia), mechanical factors (inhaled object or a lung tumor) or inhaling toxic substances.

Wikipedia : 73 Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung.... more...

Related Diseases for Bronchiectasis

Diseases in the Bronchiectasis family:

Bronchiectasis 1 Bronchiectasis 2
Bronchiectasis 3

Diseases related to Bronchiectasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 594)
# Related Disease Score Top Affiliating Genes
1 idiopathic bronchiectasis 32.4 SCNN1G SCNN1B SCNN1A CFTR-AS1 CFTR
2 bronchiectasis with or without elevated sweat chloride 1 31.9 USP11 STAT1 SCNN1B CFTR-AS1 CFTR BRWD1
3 nontuberculous mycobacterial lung disease 31.6 TLR2 CFTR
4 primary ciliary dyskinesia 31.5 USP11 SERPINA1 MBL2 ELANE DNAI1 DNAH5
5 bronchial disease 31.2 TLR2 SERPINA3 ELANE CXCL8 CFTR
6 haemophilus influenzae 31.2 TLR2 CXCL8
7 aspergillosis 30.9 TLR2 MBL2 ELANE CXCL8 CFTR
8 bronchiolitis obliterans 30.9 MPO MMP8 CXCL8
9 cystic fibrosis 30.7 TLR2 SERPINA1 SCNN1G SCNN1B SCNN1A MPO
10 alpha-1-antitrypsin deficiency 30.7 SERPINA3 SERPINA1 MPO ELANE CXCL8 CFTR
11 bronchitis 30.6 TLR2 STAT1 SERPINA1 MPO ELANE CXCL8
12 respiratory failure 30.6 SERPINA3 SERPINA1 MPO MMP8 ELANE CXCL8
13 mycobacterium abscessus 30.5 TLR2 SERPINA1 CXCL8 CFTR
14 ulcerative colitis 30.5 MPO CXCL8 CTSG BPI
15 pulmonary disease, chronic obstructive 30.4 TLR2 SERPINA3 SERPINA1 MPO MMP8 ELANE
16 pulmonary fibrosis, idiopathic 30.4 SERPINA1 MPO MMP8 ELANE CXCL8
17 pulmonary emphysema 30.4 SERPINA3 SERPINA1 MMP8 ELANE CXCL8
18 bronchopneumonia 30.3 SERPINA3 MPO ELANE CXCL8
19 pleurisy 30.3 TLR2 MPO CXCL8
20 glomerulonephritis 30.3 MPO MBL2 ELANE CTSG
21 extrinsic allergic alveolitis 30.3 MPO ELANE CXCL8
22 cholangitis 30.3 MPO CXCL8 CFTR
23 anca-associated vasculitis 30.3 SERPINA1 MPO
24 rheumatoid arthritis 30.2 TLR2 MPO MMP8 MBL2 ELANE CXCL8
25 otitis media 30.2 TLR2 MPO MBL2 CXCL8 BRWD1
26 sclerosing cholangitis 30.1 MPO CXCL8 CFTR
27 disease by infectious agent 30.1 TLR2 SERPINA3 SERPINA1 MBL2 CFTR
28 diarrhea 30.1 STAT1 SERPINA1 MPO CXCL8 CFTR
29 pneumonia 30.1 TLR2 SERPINA1 MPO MBL2 ELANE CXCL8
30 mycobacterium kansasii 30.1 TLR2 CXCL8
31 adult respiratory distress syndrome 30.0 MPO ELANE CXCL8 CTSG
32 lung disease 30.0 TLR2 SERPINA3 SERPINA1 MPO MMP8 MBL2
33 crescentic glomerulonephritis 30.0 MPO CTSG BPI
34 mycobacterium tuberculosis 1 30.0 TLR2 STAT1 SERPINA3 MBL2
35 bacterial pneumonia 29.9 TLR2 SERPINA3 ELANE CXCL8
36 immune deficiency disease 29.9 TLR2 STAT1 SERPINA3 MBL2 CTSG
37 mycobacterium chelonae 29.9 TLR2 CXCL8
38 vasculitis 29.9 SERPINA3 SERPINA1 MPO MBL2 ELANE CTSG
39 invasive aspergillosis 29.9 TLR2 SERPINA1 MBL2 CXCL8
40 bacterial infectious disease 29.9 TLR2 SERPINA3 MBL2 ELANE CXCL8 CFTR
41 paranasal sinus disease 29.8 MPO DNAI1 DNAH5 CXCL8 CFTR
42 chronic granulomatous disease 29.8 MPO ELANE CXCL8 CTSG
43 asthma 29.8 TLR2 STAT1 SERPINA3 SERPINA1 MPO MBL2
44 cerebral palsy 29.8 MPO MMP8 MBL2 CXCL8
45 proteasome-associated autoinflammatory syndrome 1 29.7 TLR2 STAT1 MPO ELANE CXCL8
46 candidiasis 29.7 TLR2 STAT1 MBL2 CXCL8
47 fungal infectious disease 29.7 TLR2 STAT1 CXCL8
48 chlamydia 29.7 TLR2 MBL2 CXCL8
49 granulomatosis with polyangiitis 29.6 TLR2 SERPINA1 MPO ELANE CTSG BPI
50 osteomyelitis 29.4 TLR2 STAT1 CXCL8

Comorbidity relations with Bronchiectasis via Phenotypic Disease Network (PDN): (show all 20)


Agammaglobulinemia, X-Linked Anxiety
Aspergillosis Bronchitis
Bronchopneumonia Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Idiopathic Interstitial Pneumonia
Lung Abscess Mitral Valve Disease
Osteoporosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Pulmonary Tuberculosis
Respiratory Failure Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Bronchiectasis:



Diseases related to Bronchiectasis

Symptoms & Phenotypes for Bronchiectasis

UMLS symptoms related to Bronchiectasis:


headache

MGI Mouse Phenotypes related to Bronchiectasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10 BRWD1 CFTR CTSG DNAH5 DNAI1 ELANE
2 mortality/aging MP:0010768 9.97 CFTR CTSG DNAH5 DNAI1 ELANE MPO
3 normal MP:0002873 9.65 CFTR CTSG DNAI1 ELANE SCNN1A SCNN1B
4 respiratory system MP:0005388 9.23 CFTR DNAH5 DNAI1 SCNN1A SCNN1B SCNN1G

Drugs & Therapeutics for Bronchiectasis

PubMed Health treatment related to Bronchiectasis: 62

Bronchiectasis often is treated with medicines, hydration , and chest physical therapy (CPT). Your doctor may recommend surgery if the bronchiectasis is isolated to a section of lung or you have a lot of bleeding . If the bronchiectasis is widespread and causing respiratory failure , your doctor may recommend oxygen therapy . The goals of treatment are to: Treat any underlying conditions and lung infections. Remove mucus (a slimy substance) from your lungs . Maintaining good hydration helps with mucus removal. Prevent complications. Early diagnosis and treatment of the underlying cause of bronchiectasis may help prevent further lung damage. In addition, any disease associated with the bronchiectasis , such as cystic fibrosis or immunodeficiency, also should be treated.

Drugs for Bronchiectasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
4
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Theophylline Approved Phase 4 58-55-9 2153
7
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
8
Budesonide Approved Phase 4 51333-22-3 63006 5281004
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
11 Calciferol Phase 4
12 Micronutrients Phase 4
13 Trace Elements Phase 4
14 Nutrients Phase 4
15 Calcium, Dietary Phase 4
16 Immunologic Factors Phase 4
17 Antimetabolites Phase 4
18 Anticholesteremic Agents Phase 4
19 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
20 Hypolipidemic Agents Phase 4
21 Lipid Regulating Agents Phase 4
22
Salmeterol xinafoate Phase 4 94749-08-3 56801
23 Fluticasone-Salmeterol Drug Combination Phase 4
24 Sympathomimetics Phase 4
25 Gentamicins Phase 4
26 Phosphodiesterase Inhibitors Phase 4
27 Adjuvants, Immunologic Phase 4
28 Broncho-Vaxom Phase 4
29 Astragalus Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Hormones Phase 4
32 Hormone Antagonists Phase 4
33 glucocorticoids Phase 4
34 Adrenergic Agonists Phase 4
35 Adrenergic beta-Agonists Phase 4
36 Neurotransmitter Agents Phase 4
37 Formoterol Fumarate Phase 4
38 Adrenergic Agents Phase 4
39 Cholinergic Agents Phase 4
40 Parasympatholytics Phase 4
41 Cholinergic Antagonists Phase 4
42 Bromides Phase 4
43 Budesonide, Formoterol Fumarate Drug Combination Phase 4
44 Anticonvulsants Phase 4
45 Tiotropium Bromide Phase 4 136310-93-5
46 Expectorants Phase 4
47 Respiratory System Agents Phase 4
48 Anti-Asthmatic Agents Phase 4
49 Bronchodilator Agents Phase 4
50 Immunoglobulins Phase 4

Interventional clinical trials:

(show top 50) (show all 246)
# Name Status NCT ID Phase Drugs
1 The Study on the Effects of Traditional Chinese Medicine Through a Series of N-of-1 Trials Based on the Mathematical Model of "Carryover Effect" Unknown status NCT03147443 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
2 Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis: a Double-blind Randomised Controlled Trial Unknown status NCT02507843 Phase 4 Cholecalciferol;Placebo
3 A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis Unknown status NCT01677403 Phase 4 Tobramycin;Saline
4 Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis:An Open-label Randomized Parallel Controlled Study Unknown status NCT02509091 Phase 4 Bronchoalveolar Lavage and Local Amikacin Injection
5 Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Completed NCT00816309 Phase 4
6 Bacterial Load Guided Therapy for Severe Exacerbations of Bronchiectasis Requiring IntraVenous Antibiotic Therapy- BLT Br IV Study Completed NCT02047773 Phase 4 Colomycin;Meropenem
7 A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Completed NCT01299181 Phase 4 Atorvastatin
8 Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis With Airway Limitation: a Prospective Study Completed NCT02782312 Phase 4 ICS+LABA
9 Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis Completed NCT00749866 Phase 4 Gentamicin;Saline
10 A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in Patients With Pseudomonas Aeruginosa Completed NCT01299194 Phase 4 ATORVASTATIN
11 Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Completed NCT00868075 Phase 4
12 Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis Completed NCT01684683 Phase 4 Theophylline;Placebo(for Theophylline)
13 A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Completed NCT02081963 Phase 4 Amikacin;Normal saline
14 Efficacy of Azithromycin in Treatment of Bronchiectasis Completed NCT02107274 Phase 4 Azithromycin;Placebo for Azithromycin
15 To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients Completed NCT01968421 Phase 4 OM-85 BV
16 The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Completed NCT01769898 Phase 4 Formoterol-budesonide;Theophylline;Placebo
17 A Series of N-of-1 Trials on Bronchiectasis Treated With Traditional Chinese Medicine Based on Bayesian Model Recruiting NCT04601792 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
18 Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease Recruiting NCT04765033 Phase 4 Nebulized 5% Hypertonic saline;Placebo
19 The Comparisons of the Efficacy and Safety of Inhaled LAMA or LAMA+LABA or ICS+LABA for Patients in COPD C Group With Bronchiectasis Enrolling by invitation NCT02546297 Phase 4 Symbicort;Spiriva
20 Efficacy and Safety of An'Ningpai Enteric Soft Capsuleson in Stable Non-CF Bronchiectasis With Hypersecretion: a Open-label Randomized Controlled Trial Not yet recruiting NCT04511897 Phase 4 An'ningpai
21 Efficacy and Safety of Inhaled Bronchodilator in Non-cystic Fibrosis Bronchiectasis Patients With Airflow Limitation: a Multicenter, Open-label Randomized Controlled Trial Not yet recruiting NCT04509661 Phase 4 LABA/LAMA or Placebo inhalation
22 Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study Suspended NCT03737617 Phase 4 Cuvitru 20 % Injectable Solution
23 Open Trial With Randomized Withdrawal of Treatment, to Evaluate the Efficacy of Azithromycin in the Treatment of Children With Non Cystic Fibrosis Bronchiectasis ( AZI-STOP Study ) Unknown status NCT02531984 Phase 3 Azithromycin
24 Effects of Traditional Chinese Medicine on Bronchiectasis Patients: A Multi-center, Randomized, Double-blind, Controlled Trial Unknown status NCT03443531 Phase 3 Bufei Huatan granule;Yifei Qinghua granule;Placebo Bufei Huatan granule;Placebo Yifei Qinghua granule
25 Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial Unknown status NCT03846570 Phase 3 Formoterol-beclomethasone;Placebo
26 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study Completed NCT00380315 Phase 3 AG1321001(drug)
27 Long-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy. Completed NCT02657473 Phase 2, Phase 3 tobramycin inhalation solution;Saline 0.9% inhalation solution
28 The Role of Vitamin D3 in Pediatric Bronchiectasis Severity( CF Versus Non CF Bronchioectasis) Completed NCT04411901 Phase 2, Phase 3 Cholecalciferol (vitaminD3)
29 : A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis. Completed NCT00669331 Phase 3 Inhaled mannitol;Matched control
30 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection Completed NCT01313624 Phase 3 AZLI;Placebo
31 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2) Completed NCT01314716 Phase 3 AZLI;Placebo
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3) Completed NCT01515007 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
33 The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis. Completed NCT00484263 Phase 3 Hypertonic saline 6% -
34 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension Completed NCT02104245 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
35 A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis. Completed NCT00277537 Phase 3 Mannitol;placebo
36 Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis. Completed NCT01764841 Phase 3 Ciprofloxacin DPI (BAYQ3939);Placebo
37 Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment Completed NCT00415350 Phase 3 Azithromycin
38 Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis. Completed NCT02106832 Phase 3 Ciprofloxacin (BAYQ3939) dry powder for inhalation;Ciprofloxacin (BAYQ3939) dry powder for inhalation;Placebo;Placebo
39 "A Prospective, Cross-over Randomized Trial to Assess the Efficacy and Safety of Mechanical Percussor "LEGA" Compared With Conventional Chest Physiotherapy in Adults With Chronic Bronchiectasis or Chronic Obstructive Pulmonary Disease (COPD Completed NCT01480882 Phase 2, Phase 3
40 Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis: a Randomized Double-blind Placebo-controlled Trial Completed NCT04122547 Phase 3 Roflumilast;Placebo
41 Effects of Roxithromycin on Quality of Life and Physiologic Outcomes in Bronchiectasis Patients During Treatment and Posttreatment Period Completed NCT04122040 Phase 3 Roxithromycin 300 MG;Placebo
42 A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) Completed NCT00105183 Phase 3
43 Efficacy and Safety of Inhaled Tobramycin on Bronchiectasis Colonized With Pseudomonas Aeruginosa: A Randomized, Double-blind, Parallel-group Multicenter Trial Recruiting NCT03715322 Phase 3 Tobramycin Inhalant Product;Natural saline inhalation
44 A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa) Recruiting NCT03460704 Phase 3 Colistimethate sodium;Saline Solution
45 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study Recruiting NCT04594369 Phase 3 Brensocatib 10 mg;Brensocatib 25 mg;Placebo
46 A 2x2 Factorial Randomized Open Label Trial to Determine the Clinical and Cost-effectiveness of Hypertonic Saline (HTS) 6% and Carbocisteine for Airway Clearance Versus Usual Care Over 52 Weeks in Bronchiectasis Recruiting NCT04140214 Phase 3 Hypertonic saline;Carbocysteine 750 MG
47 Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease (CleaR-MAC Trial) Recruiting NCT04616924 Phase 3 RHB-204;Placebo
48 A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis. Active, not recruiting NCT01270074 Phase 3 Azithromycin;Placebo control
49 A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa) Active, not recruiting NCT03093974 Phase 3 Colistimethate Sodium;Saline Solution
50 Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound Terminated NCT03829618 Phase 3 Topical lidocaine;Nebuliser solution;Nebuliser Suspension

Search NIH Clinical Center for Bronchiectasis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Acetylcysteine

Cochrane evidence based reviews: bronchiectasis

Genetic Tests for Bronchiectasis

Genetic tests related to Bronchiectasis:

# Genetic test Affiliating Genes
1 Bronchiectasis 29

Anatomical Context for Bronchiectasis

MalaCards organs/tissues related to Bronchiectasis:

40
Lung, Neutrophil, Kidney, Heart, Liver, Bone, Trachea

Publications for Bronchiectasis

Articles related to Bronchiectasis:

(show top 50) (show all 9699)
# Title Authors PMID Year
1
Allergic bronchopulmonary aspergillosis. 61 54
20463254 2010
2
Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. 54 61
20167849 2010
3
Novel cftr gene sequence variation in Serbian patient with idiopathic disseminated bronchiectasis. 61 54
20334484 2010
4
Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. 61 54
19616787 2009
5
Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. 61 54
19555716 2009
6
Stable bronchiectasis is associated with low serum L-ficolin concentrations. 61 54
20298369 2009
7
Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. 54 61
18978467 2008
8
Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. 54 61
19138237 2008
9
TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. 54 61
18684966 2008
10
Could a defective epithelial sodium channel lead to bronchiectasis. 61 54
18507830 2008
11
Airway inflammation in cystic fibrosis. 61 54
18252915 2008
12
Lack of association between matrix metalloproteinase 8 promoter polymorphism and bronchiectasis in Koreans. 61 54
17728507 2007
13
The role of TAP1 and TAP2 gene polymorphism in idiopathic bronchiectasis in children. 54 61
17245734 2007
14
Toll-like receptors 2 and 4 and innate immunity in neutrophilic asthma and idiopathic bronchiectasis. 61 54
17329561 2007
15
Lack of association between the microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene and bronchiectasis among Koreans. 54 61
17207025 2007
16
CD4/CD8 ratio and cytokine levels of the BAL fluid in patients with bronchiectasis caused by sulfur mustard gas inhalation. 54 61
17224076 2007
17
Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. 54 61
17035430 2006
18
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: a pilot study. 61 54
16678503 2006
19
Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. 54 61
16476120 2006
20
Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. 61 54
16297171 2005
21
[Bronchiectasis worsening by p-ANCA (bactericidal/permeability-increasing protein) positive vasculitis. A case report and review of the literature]. 54 61
16610259 2005
22
Chronic Burkholderia multivorans bronchial infection in a non-cystic fibrosis individual with mannose binding lectin deficiency. 61 54
15681508 2005
23
CFTR mutations and polymorphisms in adults with disseminated bronchiectasis: a controversial issue. 54 61
15618592 2005
24
Indirect CFTR mutation identification by PCR/OLA anomalous electropherograms. 54 61
16379540 2005
25
Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good. 54 61
15478278 2004
26
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. 61 54
15130905 2004
27
Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? 54 61
15151509 2004
28
Atypical sinusitis in adults must lead to looking for cystic fibrosis and primary ciliary dyskinesia. 54 61
15126740 2004
29
Role of CFTR mutations in adult bronchiectasis. 61 54
15047968 2004
30
[A case of pleural effusion associated with allergic bronchopulmonary aspergillosis during a relapse of the disease]. 54 61
14727554 2003
31
The phenotypic consequences of CFTR mutations. 54 61
12940920 2003
32
Isolated idiopathic chronic pancreatitis associated with a compound heterozygosity for two mutations of the CFTR gene. 61 54
14586256 2003
33
Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. 61 54
12702549 2003
34
High frequency of T9 and CFTR mutations in children with idiopathic bronchiectasis. 61 54
12843327 2003
35
[Molecular genetics principles in cystic fibrosis. An example of genetic illness in pneumology]. 61 54
14567084 2003
36
Lymphocytes in allergic bronchopulmonary aspergillosis. 54 61
12700106 2003
37
A preliminary assessment of alpha-1 antitrypsin S and Z deficiency allele frequencies in common variable immunodeficiency patients with and without bronchiectasis. 61 54
12452840 2002
38
Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. 54 61
15463812 2002
39
Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. 54 61
11877474 2002
40
Allergic bronchopulmonary aspergillosis: a rare cause of pleural effusion. 54 61
11844130 2001
41
Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. 54 61
11719301 2001
42
Diagnosis and treatment of allergic bronchopulmonary aspergillosis. 61 54
11560305 2001
43
Recent advances in cystic fibrosis. 61 54
11420207 2001
44
In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. 54 61
11400153 2001
45
CFTR gene mutations--including three novel nucleotide substitutions--and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. 54 61
11354633 2001
46
Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. 54 61
11120902 2001
47
Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. 61 54
11292112 2000
48
Immunology of allergic bronchopulmonary aspergillosis. 54 61
15597669 2000
49
Sputum elastase in steady-state bronchiectasis. 54 61
10669685 2000
50
Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. 61 54
10669684 2000

Variations for Bronchiectasis

ClinVar genetic disease variations for Bronchiectasis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 STAT1 NM_007315.3(STAT1):c.1154C>T (p.Thr385Met) SNV Pathogenic 144006 rs587777630 GRCh37: 2:191851647-191851647
GRCh38: 2:190986921-190986921
2 BRWD1 NM_033656.4(BRWD1):c.5573A>T (p.Gln1858Leu) SNV Likely pathogenic 982437 GRCh37: 21:40570769-40570769
GRCh38: 21:39198843-39198843
3 USP11 NM_004651.3(USP11):c.1599G>A (p.Thr533=) SNV Likely pathogenic 635007 rs777516785 GRCh37: X:47101903-47101903
GRCh38: X:47242504-47242504
4 BRWD1 NM_033656.4(BRWD1):c.1016T>C (p.Leu339Ser) SNV Uncertain significance 982514 GRCh37: 21:40649265-40649265
GRCh38: 21:39277339-39277339
5 SCNN1A NM_001038.6(SCNN1A):c.1427G>A (p.Arg476Gln) SNV Uncertain significance 598965 rs72657556 GRCh37: 12:6458505-6458505
GRCh38: 12:6349339-6349339
6 MYO9A NM_006901.4(MYO9A):c.6656G>A (p.Arg2219His) SNV Uncertain significance 997446 GRCh37: 15:72142434-72142434
GRCh38: 15:71850093-71850093
7 MYO9A NM_006901.4(MYO9A):c.2344C>A (p.Gln782Lys) SNV Uncertain significance 997447 rs539244075 GRCh37: 15:72231227-72231227
GRCh38: 15:71938886-71938886
8 BRWD1 NM_033656.4(BRWD1):c.166G>A (p.Gly56Ser) SNV Uncertain significance 982435 GRCh37: 21:40684799-40684799
GRCh38: 21:39312873-39312873
9 BRWD1 NM_033656.4(BRWD1):c.523C>T (p.His175Tyr) SNV Uncertain significance 982436 GRCh37: 21:40667755-40667755
GRCh38: 21:39295829-39295829

Expression for Bronchiectasis

Search GEO for disease gene expression data for Bronchiectasis.

Pathways for Bronchiectasis

Pathways related to Bronchiectasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 TLR2 STAT1 SERPINA3 SERPINA1 MPO MMP8
2
Show member pathways
12.07 TLR2 ELANE CTSG BPI
3
Show member pathways
11.95 TLR2 STAT1 CXCL8 CFTR
4
Show member pathways
11.89 TLR2 STAT1 CXCL8 CFTR
5 11.66 TLR2 CXCL8 CTSG
6
Show member pathways
11.63 MMP8 ELANE CTSG
7 11 SCNN1G SCNN1B SCNN1A
8 10.8 SCNN1G SCNN1B SCNN1A CFTR
9 10.79 SCNN1G SCNN1B SCNN1A
10 10.04 SCNN1G SCNN1B SCNN1A CFTR

GO Terms for Bronchiectasis

Cellular components related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.06 SERPINA3 SERPINA1 SCNN1G SCNN1B SCNN1A MPO
2 extracellular region GO:0005576 10 SERPINA3 SERPINA1 MPO MMP8 MBL2 ELANE
3 extracellular space GO:0005615 9.97 SERPINA3 SERPINA1 MPO MMP8 MBL2 ELANE
4 secretory granule GO:0030141 9.67 MPO ELANE CTSG
5 collagen-containing extracellular matrix GO:0062023 9.63 SERPINA3 SERPINA1 MMP8 MBL2 ELANE CTSG
6 specific granule lumen GO:0035580 9.54 MMP8 ELANE BPI
7 9+2 motile cilium GO:0097729 9.48 DNAI1 DNAH5
8 outer dynein arm GO:0036157 9.46 DNAI1 DNAH5
9 plasma membrane protein complex GO:0098797 9.43 SCNN1G SCNN1B
10 sodium channel complex GO:0034706 9.13 SCNN1G SCNN1B SCNN1A
11 azurophil granule lumen GO:0035578 9.02 SERPINA3 MPO ELANE CTSG BPI

Biological processes related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.78 TLR2 MPO ELANE CTSG
2 sodium ion transmembrane transport GO:0035725 9.73 SCNN1G SCNN1B SCNN1A
3 defense response to Gram-positive bacterium GO:0050830 9.72 TLR2 MBL2 CTSG
4 extracellular matrix disassembly GO:0022617 9.69 MMP8 ELANE CTSG
5 antimicrobial humoral response GO:0019730 9.67 ELANE CTSG BPI
6 defense response to bacterium GO:0042742 9.65 MPO MBL2 ELANE CTSG BPI
7 sensory perception of taste GO:0050909 9.63 SCNN1G SCNN1B SCNN1A
8 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.57 TLR2 STAT1
9 neutrophil degranulation GO:0043312 9.56 TLR2 SERPINA3 SERPINA1 MPO MMP8 ELANE
10 positive regulation of immune response GO:0050778 9.54 ELANE CTSG
11 acute-phase response GO:0006953 9.54 SERPINA3 SERPINA1 MBL2
12 response to molecule of bacterial origin GO:0002237 9.52 TLR2 CXCL8
13 defense response to fungus GO:0050832 9.5 MPO ELANE CTSG
14 cellular response to aldosterone GO:1904045 9.43 SCNN1G SCNN1B
15 response to yeast GO:0001878 9.4 MPO ELANE
16 sodium ion homeostasis GO:0055078 9.33 SCNN1G SCNN1B SCNN1A
17 multicellular organismal water homeostasis GO:0050891 8.92 SCNN1G SCNN1B SCNN1A CFTR

Molecular functions related to Bronchiectasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 WW domain binding GO:0050699 9.33 SCNN1G SCNN1B SCNN1A
2 sodium channel activity GO:0005272 9.13 SCNN1G SCNN1B SCNN1A
3 ligand-gated sodium channel activity GO:0015280 8.8 SCNN1G SCNN1B SCNN1A

Sources for Bronchiectasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....